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Chondroitin sulfate tetrasaccharides: synthesis, three-
dimensional structure and interaction with midkine 
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L. de Paz,*[a] Pedro M. Nieto*[a] 
Abstract: The biological activity of midkine, a cytokine implicated in 
neurogenesis and tumorigenesis, is regulated by its binding to 
glycosaminoglycans (GAGs) such as heparin and chondroitin sulfate 
(CS). To better understand the molecular recognition of GAG 
sequences by this growth factor, we have studied here the 
interactions between synthetic chondroitin sulfate-like 
tetrasaccharides and midkine using different techniques. First, a 
synthetic approach for the preparation of CS-like oligosaccharides in 
the sequence GalNAc-GlcA was developed. A fluorescence 
polarization competition assay was then employed to analyse the 
relative binding affinities of the synthetic compounds and revealed 
that midkine interacts with CS-like tetrasaccharides in the 
micromolar range. The 3D structure of these tetramers was studied 
in detail by a combination of NMR experiments and molecular 
dynamics simulations. Saturation transfer difference (STD) NMR 
experiments indicate that the CS tetrasaccharides bind to midkine in 
an extended conformation, with similar saturation effects along the 
entire sugar chain. These results are compatible with docking 
studies suggesting an interaction of the tetrasaccharide with midkine 
in a folded structure. Overall, our study gives valuable information on 
the interaction between midkine and well-defined, chemically 
synthesized CS oligosaccharides and these data can be useful for 
the design of more active compounds that modulate the biological 
function of this protein. 
Introduction 
Chondroitin sulfate (CS) is a linear sulfated polysaccharide that 
is involved in important biological processes such as central 
nervous system development and malaria infection.[1] CS is 
formed by the repetition of disaccharide units of D-glucuronic 
acid (GlcA) and N-acetyl-D-galactosamine (GalNAc), following 
the sequence GlcA-β(1→3)-GalNAc-β(1→4), that may contain 
sulfate groups at different positions of the chain. CS has a high 
level of structural diversity due to the presence of different 
sulfate group distributions. The participation of CS in a wide 
variety of biological processes involves its interaction with 
certain proteins, and these interactions require a specific 
arrangement of sulfate groups.[2] CS oligosaccharide sequences, 
with particular sulfation motifs, are therefore responsible for 
protein recognition and subsequent activity. For instance, CS-E, 
with the disulfated sequence GlcA-GalNAc(4,6-di-OSO3), binds 
to several neurotrophins, selectins and chemokines.[3]  
 
Midkine is a heparin-binding growth factor that promotes 
development, migration and survival of several types of cells.[4] 
For example, midkine participates in neuronal adhesion, growth 
and migration, playing an important role in the development of 
the central nervous system. Moreover, high expression of 
midkine is often observed in different classes of cancer cells. 
This protein is also involved in inflammatory diseases. For all 
these reasons, midkine is a promising molecule for drug 
development. Midkine inhibitors[5] may be of great value in the 
treatment of malignant tumors and multiple sclerosis. On the 
other hand, survival-promoting activity of midkine has the 
potential to treat and prevent neuronal degeneration processes 
such as Alzheimer’s disease. 
 
Heparin and chondroitin sulfate, in particular CS-E, are known to 
bind strongly to midkine. The dissociation constant values for 
both interactions are similar, falling in the nanomolar range.[6] It 
is now well accepted that both polysaccharides, heparin and CS, 
are essential for the activity of this growth factor. As already 
mentioned, the interaction between CS and midkine is sensitive 
to the sulfation pattern and it has been demonstrated that a 
specific arrangement of sulfate groups, the 4,6-di-O-sulfated CS-
E motif, is required for binding.[2] However, a lot of questions 
remain unsolved and novel studies on the interaction between 
CS sequences and midkine are strongly demanded in order to 
discover new structure activity relationships and deepen the 
understanding of these molecular recognition events. For 
instance, it is unknown if the introduction of an additional sulfate 
group or the substitution of a glucuronic acid by an iduronic acid 
moiety in CS-E sequences, giving rise to different sulfation 
patterns and hybrid CS-dermatan sulfate chains respectively, 
can substantially affect the binding to midkine. In this context, 
homogeneous and structurally defined synthetic CS 
oligosaccharides can be very useful to study these interactions 
at the molecular level. Despite the recent advances in CS 
oligosaccharide synthesis,[7] the development of new synthetic 
approaches for this type of molecules is still of great interest. 
Importantly, chemical synthesis can also afford CS analogues 
and mimetics,[8] with non-natural sequences, that may display 
improved biological activities and novel therapeutic applications. 
 
In this manuscript, we have employed synthetic CS-like 
oligosaccharides to study their interactions with midkine. First of 
all, we have carried out the total synthesis of a CS-E 
tetrasaccharide. This derivative was incorporated in our 
collection of oligosaccharide structures that includes CS 
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tetramers with an iduronic acid unit at the non-reducing end 
instead of a GlcA, and sulfate group distributions corresponding 
to the CS-T subtype, characterised by the trisulfated 
disaccharide unit GlcA(2-OSO3)-GalNAc(4,6-di-OSO3).
[9] The 
interaction between midkine and the library of synthetic 
oligosaccharides was analysed using fluorescence polarization 
assays. We then performed a detailed analysis of the 3D 
structure of the CS tetrasaccharides by using a combination of 
NMR experiments and molecular dynamic simulations as a 
previous step for the subsequent STD NMR experiments and 
docking studies of the CS-midkine complexes.[10] 
Results and Discussion 
Synthesis of a CS tetrasaccharide with the sequence 
GalNAc-GlcA 
 
We have previously developed a synthetic strategy for the 
preparation of CS-like tetrasaccharides in the GlcA-GalNAc 
sequence (see below).[11] This approach was based on the use 
of N-trifluoroacetyl (N-TFA) protected galactosamine building 
blocks.[12] We showed that this type of GalNAc units were highly 
convenient for the synthesis of CS oligomers since the N-TFA 
protecting group ensures the selective formation of the required 
1,2-trans glycosidic bond and can be easily removed at the end 
of the route to install the naturally occurring 2-acetamido moiety. 
Besides the length and the sulfation pattern, the sequence 
(GlcA-GalNAc or GalNAc-GlcA) is another important feature to 
be considered when studying the interactions between CS 
oligosaccharides and proteins. Here, we present the total 
synthesis of CS tetrasaccharide 15 with the alternative 
sequence GalNAc-GlcA. For this purpose, we have followed the 
retrosynthetic analysis shown in Scheme 1. The tetramer 
structure was obtained by a 2+2 coupling of disaccharide units, 
prepared from key compound 7. This derivative contains a cyclic 
silylene group at positions 4 and 6 of the galactosamine unit that 
allows their selective sulfation in order to generate CS 
sequences with the biologically relevant E sulfation motif. 
Disaccharide 7 was synthesized from monosaccharides 3 and 
4[12] that were obtained on a gram-scale from commercially 
available galactosamine hydrochloride and 1,2;5,6-di-O-
isopropylidene-α-D-glucofuranose, respectively.  
 
Scheme 1. Retrosynthetic analysis for the preparation of CS tetrasaccharide 
15. 
The anomeric acetate group of compound 1[12] was selectively 
removed by treatment with hydrazine monohydrate (Scheme 2). 
Compound 2 was transformed into glycosyl trichloroacetimidate 
3 using trichloroacetonitrile and catalytic DBU. Glycosylation 
reaction between donor 3 and glucuronic acid acceptor 4 
afforded the desired disaccharide 5 in excellent 85% yield. Next, 
the protecting groups of the GalNAc moiety were rearranged to 
obtain key building block 7. The protecting group distribution of 
this derivative allows the elongation of the oligosaccharide chain 
by glycosylation of the 3-OH group. The selective hydrolysis of 
the three acetates of compound 5 in the presence of benzoate 
and benzyloxicarbonyl groups was a challenging step. Triol 6 
was obtained in an acceptable yield by using p-toluenesulfonic 
acid (3 equiv.) in a CH2Cl2/MeOH mixture.
[13] Treatment with di-
tert-butylsilyl bistriflate in pyridine gave 7 in excellent yield. As 
mentioned before, the orthogonal silylene group enables the 
selective introduction of sulfates at the end of the synthesis. 
Moreover, this cyclic silyl group has several advantages over 
4,6-O-benzylidene acetals, such as better solubility in most 
organic solvents and higher stability under acidic glycosylation 
conditions. However, it is important to note that the silylene 
group must be introduced at the disaccharide stage, after the 
formation of the GalNAc-GlcA bond, since the presence of a 4,6-
di-tert-butylsilylene group in galactosamine (and galactose) 
donors leads to the predominant formation of the α glycoside, 
even in the presence of 2-participating groups.[14] 
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Scheme 2. Reagents and conditions: a) NH2NH2·H2O, Py/AcOH, CH2Cl2, 
73%; b) Cl3CCN, DBU, CH2Cl2, 72%; c) 4, TMSOTf, CH2Cl2, 0ºC, 85%; d) p-
TsOH, CH2Cl2/MeOH, 52%; e) tBu2Si(OTf)2, Py, 84%. 
Disaccharide 7 (Scheme 3) was converted into 
trichloroacetimidate 10 by levulinoylation (→8), followed by 
removal of the 4-methoxyphenyl group (→9) and treatment with 
trichloroacetonitrile and K2CO3 (→10). Thus, disaccharide 5 can 
be transformed, on a gram-scale, in both glycosyl donor (10) 
and acceptor (7), ready for 2+2 coupling reactions and assembly 
of growing oligosaccharide chains. Tetrasaccharide 11 was 
prepared by condensation of 7 and 10. Silylene groups were 
then selectively removed by treatment with (HF)n·Py complex. 
Tetraol 12 was sulfated under microwave irradiation[15] to afford 
13 in excellent yield. The introduction of the sulfate groups at 
positions 4 and 6 of the GalNAc units, corresponding to the E 
sulfation pattern of chondroitin sulfate, was confirmed by 1H and 
13C NMR spectroscopic data, which showed typical downfield 
shifts for these positions. Basic hydrolysis of ester and amide 
groups followed by selective N-acetylation gave water-soluble 
dibenzylated tetrasaccharide 14. Finally, hydrogenolysis 
afforded fully deprotected tetramer 15 in good yield. The 
structure of this compound was confirmed by the analysis of the 
1H and 13C NMR data that are in full agreement with those 
published for similar oligosaccharides. Both 15 and its 
dibenzylated precursor 14 were included in our library of 
synthetic oligosaccharides for interaction studies with midkine. 
 
Scheme 3. Reagents and conditions: a) Lev2O, CH2Cl2, DMAP, 87%; b) CAN, 
CH2Cl2/CH3CN/H2O, 82%; c) Cl3CCN, K2CO3, CH2Cl2, quantitative; d) 7, 
TMSOTf, CH2Cl2, 0ºC, 54%; e) (HF)n·Py, THF, 0ºC, quantitative; f) SO3·Me3N, 
DMF, 100ºC, MW, 30 min, quantitative; g) LiOH, H2O2, THF; NaOH, 
MeOH/H2O; Ac2O, MeOH, Et3N, 62%; h) H2, Pd(OH)2/C, H2O/MeOH, 92%. 
Interaction of CS tetrasaccharides with midkine by 
fluorescence polarization measurements 
 
Next, we studied the interactions between midkine and our 
collection of chemically synthesized heparin[16] and CS 
oligosaccharides (Figure 1).[11-12] The library comprises CS-like 
di- and tetrasaccharides, differing in the sulfation pattern and 
sequence, including compounds 14 and 15. Tetrasaccharides 16 
and 17 have the alternative GlcA-GalNAc sequence and contain 
seven sulfate groups, a sulfation pattern corresponding to CS-
T[9a] with an additional sulfate group at position 4 of the non-
reducing end. The analysis of the binding properties of these CS 
analogs, only accessible through chemical synthesis, is highly 
interesting because it has been recently reported that 
oligosaccharides with novel “synthetic” sulfation profiles display 
relevant biological properties.[17] Compounds 18, 19, 20 and 21 
present an L-iduronic acid (IdoA) unit at the non-reducing end of 
the chain, instead of a GlcA. The presence of IdoA moieties in 
the CS chains gives rise to the so-called hybrid 
chondroitin/dermatan sulfate (CS/DS) that plays a crucial role in 
the central nervous system development.[9a, 18] Tetrasaccharides 
18 and 19 are related to the CS-T sulfate distribution while the 
sulfation profile of 20 and 21 corresponds to the chondroitin 
sulfate E type. Synthetic heparin-like oligosaccharides 24-27[16] 
were also included in the study for comparison purposes since 
midkine recognizes heparin and CS-E polysaccharidic chains 
with similar affinities.  
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Figure 1. Structures of the synthetic oligosaccharides employed in the interaction studies with midkine. Throughout the paper, unit A refers to the reducing end 
monosaccharide. 
 
In order to study the binding between these synthetic sugars and 
midkine, we have employed a competition fluorescence 
polarization assay, previously developed in our lab.[12] This 
technique is ideal for high throughput screening, requiring very 
little amount of samples for the fast analysis of biomolecular 
interactions in solution.[19] The relative binding affinities of the 
oligosaccharides were measured as their abilities to inhibit the 
interaction between a protein, midkine, and a fluorescent 
heparin probe. If an oligosaccharide binds to midkine, the 
fluorescent probe will be displaced from the protein, producing a 
decrease in the fluorescence polarization (P) value. These 
measurements were performed in 384-well microplates by using 
a standard fluorescence reader. 
   
The correct design of a competition fluorescence polarization 
experiment requires the previous analysis of the fluorescence 
probe/protein interaction.[19a, c] Therefore, we first measured the 
direct binding of the probe (a heparin hexasaccharide with a 
covalently linked fluorescein moiety[12]) to midkine (Figure 2). 
The polarizations of samples containing a fixed concentration of 
probe and increasing concentrations of midkine were recorded. 
The obtained binding curve was fitted to the equation for a one-
site binding model and the value of the dissociation constant 
(KD), 44 ± 5 nM, was determined.  
 
Figure 2. Direct binding assay for the interaction of midkine with the 
fluorescent probe. We recorded the polarizations (P) of wells containing a 
fixed concentration of probe (10 nM) and increasing concentrations of midkine 
(ranging from 12 nM to 750 nM). The ΔP values were obtained by subtracting 
the background polarization of probe solution from the polarization values of 
sample solutions (see experimental part). ΔP was plotted against midkine 
concentration and the binding curve was fitted to the equation for a one-site 
binding model. The plotted data are the averages of three replicate wells and 
the error bars represent the standard deviations. 
 
After establishing conditions for observation of the binding 
between midkine and the fluorescent probe, we carried out the 
competition assay to screen the relative binding affinities of our 
library of synthetic oligosaccharides. For this purpose, we 
recorded the polarization of samples containing fixed 
concentrations of midkine (47 nM) and fluorescent probe (10 
nM) in the presence of the different synthetic sugars. In 
competition fluorescence polarization experiments, the ratio 
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between the protein concentration and the KD value for the 
probe/protein interaction should be at least 1. Thus, we carried 
out our competition assays using a midkine concentration of 47 
nM. Regarding the inhibitor concentration, we performed an 
initial screening at 25 µM (Figure 3). Two control samples were 
also included in the experiment: the first one contained only the 
fluorescent probe and the second one contained midkine and 
probe without inhibitor. The inhibition percentages shown in 
Figure 3 were calculated by using the polarization of these two 
control samples as the reference values for 100% and 0% 
inhibition, respectively. 
 
Oversulfated tetrasaccharides 16, 17, 18 and 19 showed high 
inhibition of the midkine/probe interaction, indicating that these 
molecules strongly bound to the protein. On the contrary, 
compounds 14-15 and 20-21 displayed only low to moderate 
activity, suggesting that the number of sulfate groups is an 
important structural feature to be considered in midkine-
oligosaccharide binding, as expected for molecular recognition 
processes mainly governed by electrostatic interactions. 
However, our results also indicate that other factors, such as the 
monosaccharide sequence and the presence of hydrophobic 
benzyl protecting groups, can also influence on the binding. In 
fact, comparing the activities of CS-like tetrasaccharides with 
four sulfate groups, we observed that 14 significantly showed 
the highest inhibition values.  
 
The interaction between CS-E tetrasaccharides and midkine has 
been demonstrated by microarray[2] and surface plasmon 
resonance[20] experiments in which the sugars were immobilized 
on appropriately functionalized glass slides and gold chips, 
respectively. Tetrasaccharide 15 displays the same sulfation 
motif than the compounds employed in those experiments and 
we therefore expected its binding to midkine. However, 15 did 
not exhibit significant activity at 25 µM concentration. We then 
decided to perform a second screening at a higher inhibitor 
concentration, 250 µM (Figure S1, Supporting information). In 
this experiment, 15 bound to midkine, giving around 50% 
inhibition. A KD value of 2.6 nM has been reported for the 
interaction between midkine and a CS-E tetrasaccharide using 
surface plasmon resonance.[20] Our results point out a much 
weaker interaction between 15 and midkine, in the micromolar 
range. This discrepancy can be partially explained by the 
different nature of the binding experiment. Fluorescence 
polarization measurements evaluate the interactions in solution 
while SPR experiments analyse the binding that occurs at a 
surface on which the carbohydrate ligand was immobilized. 
 
Figure 3. Screening assay of the synthetic oligosaccharides at 25 µM 
concentration. The inhibition percentages were calculated by using the 
polarization of reference samples for 100% and 0% inhibition (see main text 
and experimental section). The data displayed are the average of two 
independent experiments, each one in three replicates, with error bars 
showing the standard deviations for these measurements. 
 
On the other hand, Figure 3 also shows that heparin di- and 
tetrasaccharide did not interact with midkine at 25 µM 
concentration, while heparin hexasaccharides 26 and 27 
displayed more than 75% inhibition. Interestingly, the large 
difference in relative binding affinities between tetra- 25 and 
hexamers 26-27 suggests that a minimum length is required for 
the strong binding of heparin oligosaccharides to midkine.  
 
CS-like tetrasaccharides that displayed more than 60% midkine 
inhibition were considered for detailed IC50 quantification. For 
this purpose, we measured the fluorescence polarization of wells 
containing a fixed concentration of midkine and probe and 
increasing concentrations of inhibitor (Figure S2). Polarization 
was then plotted against the logarithm of inhibitor concentration 
and the curve was fitted to the formula corresponding to a one-
site competitive interaction. Table 1 shows the calculated IC50 
values for compounds 16-19. The differences between these 
values (from 2.5 µM for 18 to 10.6 µM for 17) indicate that the 
presence of both an IdoA unit at the non-reducing end and 
benzyl groups at positions 3 of the uronic acid moieties slightly 
modify the relative binding affinities to midkine. Besides the 
number and position of sulfate groups, these structural 
modifications can also modulate the interactions with midkine. 
Finally, we also determined the IC50 value for 27 that proved to 
be the most potent inhibitor. 
 
Table 1. IC50 values of synthetic oligosaccharides. 
Compound 16 17 18 19 27 
IC50 (µM) 5.3 10.6 2.5 8.0 1.1 
 
Structural analysis of tetrasaccharides 
  
We have also performed a solution structural study for 
compounds 15, 17, 19 and 21 to be used in further structure-
activity relationships. These tetrasaccharides have been studied 
mainly by homonuclear NMR obtaining structural restrains: 
torsional angles from coupling constants and distances from 
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NOE quantification. These experimental data were further 
compared with the results obtained from molecular dynamics 
simulations, both with and without time averaged experimental 
restrains. All the tetrasaccharides have temperature and base 
frequency dependent NMR spectra, suggesting the presence of 
an important conformational equilibrium. The NMR experiments 
for spectral assignment, as presented in the experimental part, 
were recorded at 323 K at 400 MHz as all the signals were 
detected with a narrower shape. However, the NMR 
experiments for 3D structural calculations were registered 
between 278 and 288 K in order to increase the population of 
the most stable conformation, to avoid potential interferences 
from high-energy conformations and to ensure a more 
favourable NOE growing regime. 
We have obtained the interprotonic experimental distances from 
1D and 2D NOESY experiments at variable mixing times from 
the cross-peaks initial growing rates at low temperatures, 
between 278 and 283 K, using the Isolated Spin Pair 
Approximation (ISPA),[21] see experimental part. The 
experimental results are consistent with a general extended 
conformation for tetrasaccharides with the glycosidic linkages in 
a syn-Ψ type arrangement, detected by NOE short distances 
between protons at both flanks of the linkages (table 2). 
Coupling constants were also extracted from the spectra and 
mostly correspond to the canonical expected conformations for 
all the monosaccharide rings except for unit D of compound 21 
that has different values than expected for a single chair 
conformation (tables S1-S4, see Supporting Information).  
Table 2. NMR interprotonic distances. 
 15 17 19 21 
 
Exp. 
NMR 
MD 
Tar 
MD  
Exp.  
NMR 
MD 
Tar 
MD 
Tar 
MD  
Exp.  
NMR 
MD 
Tar 
MD 
Tar 
MD  
Exp.  
NMR 
MD Tar MD 
 
500MHz  
288K 
500ns 
300K 
8ns 
300K  
600MHz      
278K 
500ns 
300K 
8ns 
278 K 
8ns 
300 K  
600MHz   
283 K 
500ns 
300K 
8ns 
278 K 
8ns 
300K  
600MHz  
283K 
500ns 
300 K 
10ns 
300K 
A1A2    
      
3.06 3.04 4.04 3.05 
 
3.06 3.04 3.04 
A1A3 2.78 2.75 2.72  2.59 2.58 2.58 2.58 
[c] 
2.43 2.58 2.58 2.59 
[c]
 2.51 2.61 2.62 
A1A5 2.17 2.51 2.33  2.59 2.58 2.58 2.58 
[c] 
2.43 2.58 2.59 2.57 
[c]
 2.48 2.58 2.58 
A3A4     2.43 
 
2.43 2.43 
[d] 
        
A3B1     2.48 2.98 3.03 3.03 
[e] 
2.41 3.00 3.03 3.04 
[g]
 
   
A4A5     2.43 
 
2.44 2.45 
[d] 
        
A4A6     
    
 2.65 2.76 2.80 2.83 
 
2.67 2.79 2.83 
B1B2 2.38 3.04 3.04 
[a] 
2.48 2.35 2.33 2.34 
[e] 
2.41 2.34 2.34 2.45 
[g] 
   
B1B3 2.38 2.60 2.59 
[a]
 2.42 2.84 2.57 2.57 
 
2.44 2.79 2.58 2.59 
 
2.59 2.73 2.73 
B1B5 2.37 2.58 2.57 
 
2.20 2.58 2.35 2.35 
 
2.22 2.52 2.36 2.37 
 
2.34 2.49 2.49 
B2B3    
      
3.05 3.01 
      
B2B4    
      
2.76 2.81 2.75 2.74 
 
2.80 2.78 2.79 
B3B4 2.42 2.42 2.42 
      
2.76 3.02 
   
3.06 
  
B4B5    
 
3.00 
 
3.03 3.03 
 
2.88 3,.3 
      
B4B6 2.70 2.72 2.74 
              
C1B3 2.28 2.49 2.39 
              
C1B4    
 
2.21 2.31 2.29 2.31 
 
2.09 2.32 2.33 2.32 
 
2.25 2.30 2.30 
C1C2    
     
 2.53 3.04 3.04 3.04 
[h]
 3.05 3.04 3.04 
C1C3 2.50 2.72 2.62 
     
 2.53 2.57 2.57 2.57 
[h]
 2.93 2.58 2.59 
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C1C5 2.14 2.51 2.31 
     
 2.53 2.58 2.58 2.58 
[h]
 2.41 2.58 2.58 
C3D1    
 
2.40 2.35 2.32 3.32 
 
2.48 2.34 2.35 2.32 
 
2.22 2.35 2.37 
C4C5    
 
2.50 
 
2.43 2.43 
 
2.50 2.42 
   
2.96 2.58 2.95 
C4D1 2.27 2.38 2.33 
              
C4D5    
      
2.66 2.51 2.48 2.57 
    
D1D2 2.56 3.04 3.04 
[b]
 
     
2.59 2.54 2.54 2.54 
 
2.70 2.54 2.86 
D1D3 2.56 2,59 2.57 
[b] 
2.46 2.91 2.59 2.59 
[f]
 
     
2.87 4.20 2.95 
D1D5 2.49 2.56 2.56  2.46 2.59 2.50 2.51 
[f]
 
        
D2D4    
           
2.83 4.23 2.94 
D2D5    
           
2.74 3.99 2.90 
D3D4 2.42 2.42 2.42 
              
D4D5    
      
2.43 2.38 
      
[a] Overlapping B1B2-B1B3. [b] Overlapping D1D2-D1D3. [c] Overlapping A1A3-A1A5. [d] Overlapping A4A3-A4A5. [e] Overlapping A3B1-B1B2. [f] Overlapping 
D1D3-D1D5. [g] Overlapping A3B1-B1B2. [h] Overlapping C1C2-C1C3-C1C5. 
 
Next, we have performed Molecular Dynamics (MD) studies on 
the four compounds to have further structural information to be 
applied in the conformational analysis. We run MD free 
simulations on 17 using Glycam06 as previously reported for 
heparin like oligosaccharides.[22] We did process the structures 
to extract geometrical values to compare with the experimental 
data from NMR and we have found that they agreed consistently. 
The coupling constants were calculated as the weighted 
average over the length of the whole simulation for each frame, 
considering the modified Altona equation for the calculated 
instant values.[23] Only residue D, and in less extent B, presented 
some conformational flexibility that was reflected in the 
calculated coupling constant values that were deviated from the 
experimental ones (see Supporting Information, table S2). 
Interprotonic interesidue distances, however, were consistent 
with the NOE-based experimental ones (table 2). Then we 
decide to use time averaged distance restrained MD (tar-MD)[24] 
using as experimental restrains the distances between the 
protons H1 to H3 and H1 to H5 of the rings B and D.[23] In this 
case we obtained monoconformational behaviour for all the rings, 
included D (Figures 4 and 5). The coupling constant calculated 
from the MD-tar trajectories are now in agreement with the 
experimental ones that account for a stable 4C1 conformation of 
the ring D, at least in a 98.2% of the trajectory when the 
simulation was performed at 300K. When the same MD-tar was 
run at 278K no evidences of conformational changes were 
detected at all (Table 2). Tetrasacharide 15, with the opposite 
sequence as 17, also has monoconformational behaviour, with 
all the rings in 4C1 conformation as correspond to the native 
unsulfated residues (Figure 5). 
 
 
 
We then performed a similar study on 19 and 21, both 
containing an IdoA unit at the non-reducing end. It is well 
established that iduronic acid rings usually present a typical 
conformational equilibrium between the chairs 1C4 and 
4C1 and 
the skew-boat 2SO. However, the free MD of 19 showed a single 
conformational behaviour of the monosaccharide residues, even 
when the MD was launched from a 2SO skew-boat conformation 
for unit D that quickly switched to chair 1C4. When the time 
averaged restrictions were included, this behaviour was 
confirmed. Coupling constant analysis of the ring D also agrees 
with monoconformational behaviour of this ring with small 
coupling constant values in agreement with the experimental 
ones. The experimental distances are also in agreement with the 
results of the molecular dynamic simulations, both with and 
without restrictions, in which the ring D was in 1C4 conformation 
(Figure 5). 
 
Figure 4. Superimposition of the structures of tetrasaccharides 15, 17, 19 and 
21 along 8 ns MD-tar simulations. 
 
15 17
19 21
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Figure 5. Representation of puckering coordinates (θ) of tetrasaccharides 15, 
17, 19 and 21. The puckering coordinates of 21 show the presence of 
equilibrium between conformers in the non-reducing IdoA residue. 
 
In the case of 21, the non-reducing end residue, an iduronate 
ring with three free hydroxyls, presents an intense 
conformational equilibrium. This can be deduced from the 
coupling constants that have intermediate values that do not 
correspond to a single conformation. The J3HH experimental 
coupling values are coherent with a fast equilibrium between at 
least three conformations, 1C4, 
4C1, and 
2SO. Unrestrained MD 
simulations did not reproduce this equilibrium and the 1C4 
conformation was stable along the trajectory. Only scarce 
transitions to the Cremer-Pople θ=90° were detected. However, 
when the experimental distance between H2 and H5 (2.74 Å) 
was introduced as time averaged restrain on ring D, the results 
satisfied the experimental coupling constant data (see 
Supporting Information, table S4). We evaluated the results from 
the 10 ns tar-MD considering the canonical conformations 25B 
and B3O included into the same conformational group that 2SO. It 
must be emphasised that 25B and B3O conformations are the 
closest neighbours of the 2SO in the Cremer-Pople sphere 
pseudorotational equator, θ=90°. Then, considering the group 
2SO as the ensemble of 
2SO, 
25B and B3O, an 88% of the total 
population of the trajectory is represented and varies between 
1C4, 
4C1, and 
2SO (Figure 5). In addition, the weighting averaged 
theoretical coupling constant values also agreed with the 
experimental ones. 
 
All tetrasaccharides show an extended structure (figures 4 and 
6), with Φ/Ψ maps corresponding to a syn-Φ/Ψ disposition (see 
Supporting Information, figures S3-S10). When time averaged 
restrains were applied, the space visited during the MD-tar was 
reduced, fitting better with the experimental values. In the case 
of the tetrasaccharide with the opposed sequence, 15, this effect 
was even more accused, as its free MD is compatible with a 
more flexible compound (see Supporting Information, figures S3 
and S4). 
 
Interestingly enough, the structures of the four tetrasaccharides 
can be superimposed assuming the sequence inversion or shift 
in 15 with respect to the rest. Independently on the level of 
sulfation and its position, or the presence of iduronate or 
glucuronate residues, most of the glycosidic linkages adopt 
similar disposition (figure 6). 
 
Figure 6. Superimposition of the minimized structures calculated for 15 (blue), 
17 (purple), 19 (brown) and 21 (considered as two independent conformations: 
1
C4 (green) and 
2
S0 (yellow)).  
 
STD and docking 
 
The solution structure of midkine has been previously 
determined by NMR.[25] Midkine is structurally divided into two 
domains, C- and N-terminally located, joined by a hinge region. 
Although heparin binding and most of the biological activities of 
midkine are typically associated with the C-terminal domain, 
recent studies[25b] show that the N-terminal domain is also 
needed to mediate protein activity. For example, the interaction 
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with fondaparinux (a synthetic heparin pentasaccharide) 
involves, not only the C-terminal half, but also the N-terminal 
domain and the hinge. In order to better understand the process 
of association between the CS oligosaccharides and midkine, 
we have performed a STD study using 15 and 19 complexes 
with midkine. We have applied the initial rate of the STD 
amplification factors approach to better quantify the STD effects 
and decoupling them from spurious relaxation effects 
(Supporting Information, tables S5 and S6 and figures S11 and 
S12).[26] Both compounds showed moderate STD effects within 
similar range, extended along the entire chain (Figure 7). The 
largest STD effects are concentrated in the reducing end residue. 
Unfortunately, the signal overlapping prevented us from extract 
more precise structural data. Together with transfer NOE cross-
peaks, the results are compatible with the association of both 
tetrasaccharides in an extended conformation while are 
simultaneously bound to both midkine domains that are close in 
space due to the hinged structure of the protein in solution, as it 
can be seen in some of the NMR structures. This can be seen 
considering the existence of STD in both sides and along all the 
tetrasaccharide, in both cases. 
 
Figure 7. STD0 relative (top) and absolute (bottom) values for 15 and 19. 
 
We have performed a docking study using the coordinates of the 
NMR structure of midkine and the tetrasaccharides 15, 17, 19 
and 21 (figures S13-S17). We have chosen one of the models 
from the NMR structures ensemble (model 3 from 10) calculated 
for midkine-A (pdb code: 2LUT) in which the two binding 
domains are close in the 3D structure. We first have constructed 
the complex using AutodockTools-1.5.6 from Autodock Vina 
either in automatic mode (considering all the residues within 10 
Å) or only the clusters described by Lim et al[25b]: Cluster 1: K82-
R84-K105; Cluster2: Q89-K90-L92; Cluster3: R38-R47; 
Cluster4: K48-K50-R52; Hinge: K58-K59. The complexes thus 
obtained were then subjected to Flexible Docking using Glyde 
as implemented in Maestro suite. In all the obtained models, the 
tetrasaccharides interact simultaneously with both 
glycosaminoglycan recognition domains of midkine-A, adopting 
the protein a folded conformation (Figure 8). Interestingly, all the 
carbohydrates are in the internal region of the protein loop 
formed by the two recognition domains, and surrounded by the 
unstructured regions of midkine, explaining the STD effects seen 
in both faces of the oligosaccharides (Figure 8). In addition, 
these structures are also compatible with transfer NOE results 
that account for extended glicosidic linkages. Unfortunately, all 
the attempts to quantify the STD using CORCEMA-ST did not 
converge to a satisfactory structure. 
 
Figure 8. Docking-calculated structures for complexes between midkine and 
the studied tetrasaccharides. Superimposition of the structures with the best 
docking coefficient for one representative of all the tetrasaccharides (left), 
superimposition of all the structures obtained using docking 10 each (right). 
Conclusions 
We have developed an efficient approach for the synthesis of 
CS oligosaccharides following the GalNAc-GlcA sequence, 
illustrated by the preparation of CS-E tetrasaccharide 15. This 
strategy can be potentially extended to the synthesis of longer 
sequences with different sulfation motifs, by iterative 
glycosylation reactions and standard manipulation/sulfation of 
galactosamine 4-OH/6-OH groups, using disaccharide 7 as key 
building block. The present approach improves our previous 
strategy for CS oligomers with the alternative sequence GlcA-
GalNAc, in terms of total number of steps. Thus, the crucial 
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cyclic sylilene group, which favors the undesired 1,2-cis 
glycosidic bond,  is now introduced at the disaccharide stage, 
after the construction of the GalNAc-GlcA 1,2-trans linkage. 
 
We have also demonstrated that our fluorescence polarization 
competition experiment is an excellent platform for the rapid 
analysis of the interactions between midkine and CS-like 
oligosaccharides. Our results show that the binding strength 
mainly depends on the density of sulfate groups: the relative 
affinities of CS-T related structures, in the low micromolar range, 
are much higher than those corresponding to the CS-E 
tetramers. Additionally, these data suggest that other structural 
features of CS-like molecules, such as the presence of 
hydrophobic benzyl protecting groups and IdoA units instead of 
GlcA, can also modulate the binding to midkine. Interestingly, we 
have shown that midkine binds to the CS-E tetrasaccharide 15, 
although with much less affinity (high micromolar range) than 
previously reported, probably due to the different nature of the 
binding experiments. 
 
High-resolution NMR experiments provide interprotonic 
distances for the studied tetrasaccharides that are consistent 
with an extended conformation and a syn-Φ/Ψ disposition for 
glycosidic bonds. Experimental coupling constants values show 
that all the monosaccharide rings adopt single chair 
conformations, except residue D of tetrasaccharide 21 that 
presents the typical conformational equilibrium of iduronic acid 
units between the chairs 1C4 and 
4C1 and the skew-boat 
2SO. 
These results were confirmed with molecular dynamic 
simulations in which the best fit between theoretical and 
experimental values was obtained when time averaged restrains 
were applied. The binding of the CS tetrasaccharides to midkine 
was also evaluated by STD-NMR and docking studies. STD 
experiments show that the tetrasaccharides interact in an 
extended conformation, along the entire chain, while docking 
results are compatible with a simultaneous association of the 
sugars with both domains of midkine, in a folded protein 
conformation. This binding mode, mainly in the internal region of 
the midkine formed by the two folded domains and the hinge, is 
in good agreement with that previously proposed for the 
interaction between midkine and fondaparinux. 
            
Experimental Section 
General synthetic procedures: Thin layer chromatography (TLC) 
analyses were performed on silica gel 60 F254 precoated on aluminium 
plates (Merck) and the compounds were detected by staining with 
sulfuric acid/ethanol (1:9), with cerium (IV) sulfate (10 
g)/phosphomolybdic acid (13 g)/sulfuric acid (60 mL) solution in water (1 
L), or with anisaldehyde solution [anisaldehyde (25 mL) with sulfuric acid 
(25 mL), ethanol (450 mL) and acetic acid (1 mL)], followed by heating at 
over 200ºC. Column chromatography was carried out on silica gel 60 
(0.2-0.5 mm, 0.2-0.063 mm or 0.040-0.015 mm; Merck). Optical rotations 
were determined with a Perkin-Elmer 341 polarimeter. 1H- and 13C-NMR 
spectra were acquired on Bruker DPX-300, Avance III-400 and DRX-500 
spectrometers. Unit A refers to the reducing end monosaccharide in the 
NMR data. Electrospray mass spectra (ESI MS) were carried out with an 
Esquire 6000 ESI-Ion Trap from Bruker Daltonics. High resolution mass 
spectra (HR MS) were carried out by CITIUS (Universidad de Sevilla). 
Microwave-based sulfation reactions were performed using a Biotage 
Initiator Eight synthesizer in sealed reaction vessels. 
3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-α,β-D-
galactopyranose (2): Compound 1 (2.76 g, 6.23 mmol) was dissolved in 
CH2Cl2 (25 mL) and hydrazine monohydrate (25 mL of a 0.5 M solution in 
Py/AcOH 3:2) was added. After stirring at room temperature for 1h, the 
reaction mixture was quenched with acetone (2 mL). The mixture was 
diluted with CH2Cl2 and washed with 1 m HCl aqueous solution, 
saturated NaHCO3 aqueous solution and H2O. The organic layer was 
dried (MgSO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (hexane-EtOAc 2:1) to afford 2 (1.82 
g, 73%). TLC (hexane-EtOAc 3:2) Rf 0.31; 1H-NMR (500 MHz, CDCl3) 
(data for α anomer): δ 6.68 (d, 1H, JNH,2 = 9.5 Hz, NH), 5.46 (d, 1H, J3,4 = 
2.5 Hz, H-4), 5.42 (d, 1H, J1,2 = 4.0 Hz, H-1), 5.34 (dd, 1H, J2,3 = 11.3 Hz, 
H-3), 4.60 (m, 1H, H-2), 4.48 (t, 1H, J5,6a = J5,6b = 6.3 Hz, H-5), 4.17 (m, 
2H, H-6a, H-6b), 2.21, 2.09, 2.03 (3s, 9H, OAc); 13C-NMR (75 MHz, 
CDCl3): δ 171.1, 171.0, 170.4 (3CO), 157.6 (q, COCF3), 115.6 (q, 
COCF3), 91.4 (C-1), 67.8 (C-3), 67.3 (C-4), 66.6 (C-5), 62.1 (C-6), 48.7 
(C-2), 20.7, 20.6, 20.4 (3CH3); HR MS: m/z: calcd for C14H18F3NO9Na: 
424.0826; found: 424.0826 [M+Na]+. 
O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido-α,β-D-
galactopyranosyl) trichloroacetimidate (3): Trichloroacetonitrile (7.8 
mL, 78 mmol) and catalytic DBU (78 µL, 0.52 mmol) were added to a 
solution of 2 (2.08 g, 5.2 mmol) in dry CH2Cl2 (20 mL). After stirring for 4 
h at room temperature, the reaction mixture was concentrated to dryness. 
The residue was purified by a short silica gel column (hexane-EtOAc 3:1 
+ 1% Et3N) to afford 3 (2.04 g, 72%). TLC (hexane-EtOAc 2:1 + 1% Et3N) 
Rf 0.43; 1H-NMR (300 MHz, CDCl3) (data for α anomer): δ 8.85 (s, 1H, 
NH(TCA)), 6.59 (d, 1H, JNH,2 = 9.0 Hz, NH(TFA)), 6.47 (d, 1H, J1,2 = 3.6 
Hz, H-1), 5.53 (br d, 1H, H-4), 5.35 (dd, 1H, J3,4 = 3.2 Hz, J2,3 = 11.2 Hz, 
H-3), 4.77 (m, 1H, H-2), 4.38 (m, 1H, H-5), 4.14 (m, 2H, H-6a, H-6b), 
2.20, 2.04, 2.03 (3s, 9H, OAc); 13C-NMR (75 MHz, CDCl3): δ 171.1, 
170.3, 170.1 (3CO), 160.1 (C=NH), 157.5 (q, COCF3), 115.5 (q, COCF3), 
94.3 (C-1), 90.6 (CCl3), 69.2 (C-5), 67.7 (C-3), 66.3 (C-4), 61.1 (C-6), 
48.2 (C-2), 20.62, 20.59, 20.4 (3CH3); ESI MS: m/z: calcd for 
C16H18Cl3F3N2O9Na: 569.0; found: 569.1 [M+Na]
+. 
Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(3,4,6-tri-O-
acetyl-2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-β-D-
glucopyranoside] uronate (5): Donor 3 (2.02 g, 3.70 mmol) and 
acceptor 4 (1.40 g, 2.40 mmol) were dissolved in dry CH2Cl2 (30 mL) in 
the presence of freshly activated 4Å molecular sieves. After stirring for 15 
min at 0ºC, TMSOTf (134 µL, 0.74 mmol) was added under an argon 
atmosphere. After stirring for 15 min at 0ºC, the reaction mixture was 
neutralized with Et3N, filtered and concentrated to dryness. The residue 
was purified by column chromatography (hexane-EtOAc 3:1→2:1) to 
afford 5 (1.96 g, 85%). TLC (hexane-EtOAc 2:1) Rf 0.16; [α]20D –4º (c 1.0, 
CHCl3); 
1H-NMR (400 MHz, CDCl3): δ 7.98 (d, 2H, Ar), 7.60 (t, 1H, Ar), 
7.49-7.44 (m, 7H, Ar), 7.19-7.13 (m, 5H, Ar), 6.90 (m, 2H, Ar), 6.73 (m, 
2H, Ar), 6.58 (d, 1H, JNH,2 = 8.8 Hz, NH), 5.48 (dd, 1H, J2,3 = 8.8 Hz, H-2), 
5.39 (d, 1H, CH2(Bn)), 5.22 (d, 1H, J3,4 = 2.8 Hz, H-4’), 5.13 (d, 1H, 
CH2(Bn)), 5.04 (d, 1H, J1,2 = 7.2 Hz, H-1), 4.87 (d, 1H, CH2(Bn)), 4.68-
4.62 (m, 2H, H-3’, CH2(Bn)), 4.25 (m, 1H, H-2’), 4.16 (t, 1H, H-4), 4.09 (m, 
2H, H-1’, H-5), 3.97 (dd, 1H, J6a,6b = 11.2 Hz, H-6’a), 3.89-3.82 (m, 2H, H-
3, H-6’b), 3.75 (s, 3H, Me (OMP)), 3.43 (t, 1H, J5,6a = J5,6b = 7.0 Hz, H-5’), 
2.15, 2.06, 2.02 (3s, 9H, OAc); 13C-NMR (100 MHz, CDCl3): δ 170.4, 
170.3, 170.1, 168.9, 165.0 (5CO), 157.6 (q, COCF3), 155.8-114.5 (Ar), 
115.8 (q, COCF3), 100.8 (C-1), 100.4 (C-1’), 79.4 (C-3), 78.5 (C-4), 75.0 
(CH2(Bn)), 74.4 (C-5), 72.7 (C-2), 70.8, 70.6 (C-3’, C-5’), 68.0 (CH2(Bn)), 
66.0 (C-4’), 60.6 (C-6’), 55.6 (Me (OMP)), 51.0 (C-2’), 20.7, 20.6, 20.4 
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(3CH3); HR MS: m/z: calcd for C48H48F3NO17Na: 990.2767; found: 
990.2764 [M+Na]+. 
Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(2-deoxy-2-
trifluoroacetamido-β-D-galactopyranosyl)-β-D-glucopyranoside] 
uronate (6): Compound 5 (1.96 g, 2.03 mmol) was dissolved in 
CH2Cl2/MeOH (18 mL/2 mL) and p-toluenesulfonic acid was added (1.16 
g, 6.08 mmol). After stirring for 11 h at room temperature, the reaction 
mixture was diluted with CH2Cl2 and washed with saturated aqueous 
NaHCO3 and H2O. The organic phase was dried (MgSO4), filtered and 
concentrated to dryness. The residue was purified by column 
chromatography (CH2Cl2-MeOH 40:1) to afford 6 as a amorphous white 
solid (884 mg, 52%). TLC (CH2Cl2-MeOH 30:1) Rf 0.20; [α]
20
D +22º (c 1.0, 
CHCl3); 
1H-NMR (500 MHz, CDCl3): δ 8.01 (d, 2H, Ar), 7.60 (t, 1H, Ar), 
7.49-7.39 (m, 8H, Ar, NH), 7.21-7.18 (m, 5H, Ar), 6.92 (m, 2H, Ar), 6.74 
(m, 2H, Ar), 5.50 (t, 1H, H-2), 5.37 (d, 1H, CH2(Bn)), 5.19 (d, 1H, 
CH2(Bn)), 5.06 (d, 1H, J1,2 = 7.5 Hz, H-1), 4.90 (d, 1H, CH2(Bn)), 4.63 (d, 
1H, CH2(Bn)), 4.16-4.09 (m, 2H, H-4, H-5), 3.98 (m, 2H, H-1’, H-2’), 3.84 
(t, 1H, J2,3 = J3,4 = 9.0 Hz, H-3), 3.80 (br s, 1H, H-4’), 3.76 (s, 3H, Me 
(OMP)), 3.67 (dd, 1H, J5,6a = 6.0 Hz, J6a,6b = 11.5 Hz, H-6’a), 3.61 (br d, 
1H, H-6’b), 3.30 (br d, 1H, H-3’), 3.05 (m, 1H, H-5’); 13C-NMR (100 MHz, 
CDCl3-CD3OD 9:1): δ 168.0, 165.2 (2 x CO), 158.4 (q, COCF3), 155.5-
114.3 (Ar), 115.9 (q, COCF3), 100.6 (C-1), 100.0 (C-1’), 79.7 (C-3), 76.2 
(C-4), 75.8 (CH2(Bn), C-5’), 74.2 (C-5), 72.4 (C-2), 70.8 (C-3’), 68.3 (C-4’), 
67.5 (CH2(Bn)), 61.8 (C-6’), 55.3 (Me (OMP)), 53.6 (C-2’); HR MS: m/z: 
calcd for C42H42F3NO14Na: 864.2450; found: 864.2447 [M+Na]
+. 
Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-tert-
butylsilylene-2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-β-
D-glucopyranoside] uronate (7): Compound 6 (100 mg, 0.12 mmol) 
was dissolved in dry Py (4 mL) and cooled (0ºC). Di-tert-butylsilyl 
bis(trifluoromethanesulfonate) (42 µL, 0.13 mmol) was added and the 
mixture was stirred at room temperature for 25 min. The reaction was 
quenched with MeOH (0.5 mL), diluted with EtOAc (50 mL), and washed 
with 1 m HCl, saturated aqueous NaHCO3, and H2O. The organic phase 
was dried (MgSO4), filtered and concentrated to dryness. The residue 
was purified by column chromatography (toluene-EtOAc 5:1) to afford 7 
as a colorless oil (98 mg, 84%). TLC (toluene-EtOAc 5:1) Rf 0.29; [α]20D 
+33º (c 1.0, CHCl3); 
1H-NMR (400 MHz, CDCl3): δ 7.94 (d, 2H, Ar), 7.60 
(t, 1H, Ar), 7.46-7.38 (m, 7H, Ar), 7.22-7.07 (m, 6H, Ar, NH), 6.90 (m, 2H, 
Ar), 6.72 (m, 2H, Ar), 5.49 (t, 1H, H-2), 5.34 (d, 1H, CH2(Bn)), 5.12 (d, 1H, 
CH2(Bn)), 5.05 (d, 1H, J1,2 = 6.8 Hz, H-1), 5.00 (d, 1H, CH2(Bn)), 4.63 (d, 
1H, CH2(Bn)), 4.30-4.18 (m, 6H, H-4, H-1’, H-2’, H-4’, H-6’a, H-6’b), 4.14 
(d, 1H, J4,5 = 9.2 Hz, H-5), 3.89 (t, 1H, J2,3 = J3,4 = 8.4 Hz, H-3), 3.75 (s, 
3H, Me (OMP)), 3.21 (dd, 1H, J2,3 = 9.6 Hz, J3,4 = 2.8 Hz, H-3’), 3.08 (br s, 
1H, H-5’), 1.09, 1.05 (2s, 18H, C(CH3)3); 
13C-NMR (100 MHz, CDCl3): δ 
170.0, 165.1 (2 x CO), 158.2 (q, COCF3), 155.7-114.5 (Ar), 116.1 (q, 
COCF3), 102.0 (C-1’), 100.6 (C-1), 80.5 (C-4), 79.7 (C-3), 75.5 (CH2(Bn)), 
74.5 (C-5), 73.3 (C-3’), 73.0 (C-2), 72.1 (C-5’), 71.9 (C-4’), 68.0 
(CH2(Bn)), 66.5 (C-6’), 55.6 (Me (OMP)), 53.0 (C-2’), 27.6, 27.4 
(C(CH3)3), 23.4, 20.6 (C(CH3)3); HR MS: m/z: calcd for 
C50H58F3NO14NaSi: 1004.3471; found: 1004.3451 [M+Na]
+. 
Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-tert-
butylsilylene-2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-
galactopyranosyl)-β-D-glucopyranoside] uronate (8): Lev2O 
preparation: LevOH (241 µL, 2.34 mmol) was added at 0ºC to a solution 
of 1,3-dicyclohexylcarbodiimide (241 mg, 1.17 mmol) in CH2Cl2 (4 mL). 
After stirring 5 min at room temperature, the mixture was cooled and 
filtered, and the urea precipitate was washed with additional CH2Cl2 (2 
mL), to give 6 mL of a 0.20 m Lev2O solution. 
Lev2O (6 mL of a 0.20 m solution in CH2Cl2) was added at room 
temperature to a mixture of 7 (380 mg, 0.39 mmol) and DMAP (7 mg, 
0.06 mmol). The mixture was stirred for 1 h, diluted with CH2Cl2, and 
washed with saturated aqueous NaHCO3, and H2O. The organic phase 
was dried (MgSO4), filtered and concentrated to dryness. The residue 
was purified by column chromatography (toluene-EtOAc 5:1) to afford 8 
as a white foam (364 mg, 87%). TLC (toluene-EtOAc 4:1) Rf 0.37; [α]
20
D 
+30.5º (c 1.0, CHCl3); 
1H-NMR (500 MHz, CDCl3): δ 7.92 (d, 2H, Ar), 
7.57 (t, 1H, Ar), 7.44-7.38 (m, 7H, Ar), 7.21-7.07 (m, 5H, Ar), 6.91-6.86 
(m, 3H, Ar, NH), 6.70 (m, 2H, Ar), 5.46 (t, 1H, H-2), 5.30 (d, 1H, CH2(Bn)), 
5.09 (d, 1H, CH2(Bn)), 5.05 (d, 1H, J1,2 = 6.8 Hz, H-1), 4.96 (d, 1H, 
CH2(Bn)), 4.64 (d, 1H, CH2(Bn)), 4.54 (m, 2H, H-2’, H-3’), 4.49 (br s, 1H, 
H-4’), 4.40 (d, 1H, J1,2 = 7.7 Hz, H-1’), 4.24 (t, 1H, H-4), 4.18 (m, 2H, H-
6’a, H-6’b), 4.11 (d, 1H, J4,5 = 9.0 Hz, H-5), 3.89 (t, 1H, J2,3 = J3,4 = 8.2 Hz, 
H-3), 3.73 (s, 3H, Me (OMP)), 3.06 (br s, 1H, H-5’), 2.82-2.56 (m, 4H, 
CH2(Lev)), 2.20 (s, 3H, CH3(Lev)), 1.04, 1.02 (2s, 18H, C(CH3)3); 
13C-NMR (125 MHz, CDCl3): δ 206.7, 172.7, 170.0, 165.4 (4 x CO), 
157.9 (q, COCF3), 156.0-114.8 (Ar), 116.2 (q, COCF3), 102.3 (C-1’), 
100.9 (C-1), 80.4 (C-4), 79.9 (C-3), 75.4 (CH2(Bn)), 74.9 (C-5), 74.1 (C-
3’), 73.4 (C-2), 72.3 (C-5’), 69.8 (C-4’), 68.2 (CH2(Bn)), 66.9 (C-6’), 55.9 
(Me (OMP)), 50.3 (C-2’), 38.1 (CH2(Lev)), 30.0 (CH3(Lev)), 28.6 
(CH2(Lev)), 28.0, 27.7 (C(CH3)3), 23.7, 20.8 (C(CH3)3); HR MS: m/z: 
calcd for C55H64F3NO16NaSi: 1102.3839; found: 1102.3842 [M+Na]
+. 
Benzyl [2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-tert-butylsilylene-2-
deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-
α,β-D-glucopyranose] uronate (9): CAN (2.7 mL of a 0.63 m solution in 
H2O) was added to a solution of 8 (456 mg, 0.422 mmol) in 
CH2Cl2/MeCN (1:2; 24.3 mL). After stirring for 1 h at room temperature, 
the reaction mixture was diluted with EtOAc, washed with H2O, saturated 
aqueous NaHCO3, and H2O. The organic phase was dried (MgSO4), 
filtered and concentrated to dryness. The residue was purified by column 
chromatography (toluene-EtOAc 4:1) to afford 9 as an orange foam (336 
mg, 82%, mixture of α/β anomers). TLC (toluene-EtOAc 4:1) Rf 0.24; 
1H-NMR (400 MHz, CDCl3) (data for α anomer): δ 7.96 (d, 2H, Ar), 7.57 (t, 
1H, Ar), 7.49-7.12 (m, 12H, Ar), 7.06 (d, 1H, J2,NH = 8.3 Hz, NH), 5.55 (t, 
1H, H-1), 5.41 (d, 1H, CH2(Bn)), 5.15-5.08 (m, 2H, CH2(Bn), H-2), 5.00 (d, 
1H, CH2(Bn)), 4.66 (d, 1H, CH2(Bn)), 4.54-4.46 (m, 4H, H-2’, H-3’, H-4’, 
H-5),  4.29 (d, 1H, J1,2 = 7.9 Hz, H-1’), 4.20-4.10 (m, 3H, H-3, H-6’a, H-
6’b), 4.02 (t, 1H, J3,4 = J4,5 = 8.2 Hz, H-4), 3.76 (d, 1H, J1,OH = 4.7 Hz, 
OH), 2.96 (br s, 1H, H-5’), 2.81-2.56 (m, 4H, CH2(Lev)), 2.20 (s, 3H, 
CH3(Lev)), 1.04, 1.01 (2s, 18H, C(CH3)3); 
13C-NMR (100 MHz, CDCl3) 
(data for α anomer): δ 206.5, 172.3, 170.7, 165.8 (4 x CO), 157.7 (q, 
COCF3), 138.1-125.3 (Ar), 116.0 (q, COCF3), 101.5 (C-1’), 90.1 (C-1), 
79.9 (C-4), 76.8 (C-3), 75.2 (CH2(Bn)), 73.7 (C-5 or C-3’), 72.2 (C-2), 
71.8 (C-5’), 70.8 (C-5 or C-3’), 69.5 (C-4’), 67.8 (CH2(Bn)), 66.5 (C-6’), 
50.0 (C-2’), 37.8 (CH2(Lev)), 29.7 (CH3(Lev)), 28.2 (CH2(Lev)), 27.6, 27.3 
(C(CH3)3), 23.3, 20.5 (C(CH3)3); HR MS: m/z: calcd for 
C48H58F3NO15NaSi: 996.3420; found: 996.3421 [M+Na]
+. 
O-[Benzyl 2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-tert-butylsilylene-2-
deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-
α,β-D-glucopyranosyluronate] trichloroacetimidate (10): 
Trichloroacetonitrile (1.26 mL, 12.6 mmol) and K2CO3 (41 mg, 0.30 
mmol) were added to 9 (246 mg, 0.25 mmol) in dry CH2Cl2 (4 mL) under 
an argon atmosphere. After stirring at room temperature for 8 h, the 
mixture was filtered and concentrated in vacuo to give 10 as a brown oil 
(279 mg, quantitative, mixture of α/β anomers). TLC (CH2Cl2-MeOH 80:1) 
Rf 0.67 and 0.53; 1H-NMR (500 MHz, CDCl3) (data for a 1:1 α/β mixture): 
δ 8.66, 8.62 (2s, 2H, NHα and NHβ), 7.89-7.10 (m, 31H, Ar and NH), 
6.92 (br s, 1H, NH), 6.59 (d, 1H, J1,2 = 3.7 Hz, H-1α), 6.01 (d, 1H, J1,2 = 
6.5 Hz, H-1β), 5.50-5.47 (m, 2H, H-2β, CH2(Bn)), 5.39-5.34 (m, 2H, H-2α, 
CH2(Bn)), 5.14 (m, 2H, CH2(Bn)), 4.94 (d, 1H, CH2(Bn)), 4.89 (d, 1H, 
CH2(Bn)), 4.66 (m, 2H, CH2(Bn)), 4.52-3.86 (m, 18H, H-3, H-4, H-5, H-1’, 
H-2’, H-3’, H-4’, H-6’a, H-6’b), 2.96 (br s, 1H, H-5’β), 2.79-2.74 (m, 4H, 
CH2(Lev)), 2.69 (br s, 1H, H-5’α), 2.59 (m, 4H, CH2(Lev)), 2.19 (2s, 6H, 
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CH3(Lev)), 1.02-0.99 (2s, 36H, C(CH3)3); ESI MS: m/z: calcd for 
C50H58Cl3F3N2O15SiNa: 1141.3; found: 1141.4 [M+Na]
+. 
4-Methoxyphenyl O-(4,6-O-di-tert-butylsilylene-2-deoxy-3-O-
levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-(1→4)-O-
(benzyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranosyluronate)-(1→3)-
O-(4,6-O-di-tert-butylsilylene-2-deoxy-2-trifluoroacetamido-β-D-
galactopyranosyl)-(1→4)-benzyl 2-O-benzoyl-3-O-benzyl-β-D-
glucopyranosiduronate (11): Donor 10 (208 mg, 0.186 mmol) and 
aceptor 7 (71 mg, 0.072 mmol) were coevaporated with toluene, 
concentrated in vacuo and dissolved in dry CH2Cl2 (3 mL) in the 
presence of freshly activated 4Å molecular sieves (225 mg). After stirring 
for 15 min at 0 ºC, TMSOTf (200 µL of a 0.19 M solution in dry CH2Cl2) 
was added under an argon atmosphere. After stirring for 30 min at 0ºC, 
the reaction mixture was neutralized with Et3N, filtered, and concentrated 
to dryness. The residue was purified by column chromatography (CH2Cl2 
100% → CH2Cl2-acetone 80:1) to afford 11 as a white foam (75 mg, 
54%). TLC (CH2Cl2-acetone 80:1) Rf 0.23; [α]
20
D +19.8º (c 1.0, CHCl3); 
1H-NMR (400 MHz, CDCl3): δ 7.95 (m, 4H, Ar), 7.58 (m, 2H, Ar), 7.49-
7.09 (m, 24H, Ar), 6.89-6.87 (m, 3H, Ar, NH), 6.69 (m, 2H, Ar), 6.51 (br d, 
1H, J2,NH = 8.2 Hz, NH), 5.47 (t, 1H, J1,2 = J2,3 = 7.0 Hz, H-2A or C), 5.39 
(d, 1H, CH2(Bn)), 5.27 (t, 1H, J1,2 = J2,3 = 7.4 Hz, H-2A or C), 5.18-5.07 
(m, 5H, H-1A, H-1C, 3 x CH2(Bn)), 4.89 (2d, 2H, CH2(Bn)), 4.69 (m, 2H, 
H-1B or D, CH2(Bn)), 4.56 (d, 1H, CH2(Bn)), 4.47-4.44 (m, 4H, H-2B or D, 
H-4B, H-4D, H-3D), 4.35 (t, 1H, J3,4 = J4,5 = 7.8 Hz, H-4A or C), 4.18-3.95 
(m, 9H, H-2B or D, H-6B, H-6D, H-1B or D, H-5A, H-5C, H-4A or C), 3.90 
(t, 1H, H-3A or C), 3.83-3.76 (m, 2H, H-3B, H-3A or C), 3.73 (s, 3H, Me 
(OMP)), 3.00-2.86 (2 br s, 2H, H-5B, H-5D), 2.80-2.60 (m, 4H, CH2(Lev)), 
2.21 (s, 3H, CH3(Lev)), 1.04-0.96 (m, 36H, C(CH3)3); 
13C-NMR (100 MHz, 
CDCl3): δ 206.3, 172.4, 169.4, 168.9, 165.1, 165.0 (6 x CO), 157.5 (2q, 
COCF3), 155.5-114.3 (Ar), 117.2 (2q, COCF3), 101.3, 101.2 (C-1B, C-1D), 
100.4, 100.0 (C-1A, C-1C), 79.7, 79.6 (C-3A, C-3C), 79.3, 78.6 (C-4A, C-
4C), 76.6 (C-3B), 74.6, 74.55, 74.48, 74.2 (C-5A, C-5C, CH2(Bn)), 73.4, 
73.1, 72.2, 72.1, 71.9, 71.7, 69.3 (C-5B, C-5D, C-2A, C-2C, C-4B, C-4D, 
C-3D), 67.9, 67.5 (CH2(Bn)), 66.6, 66.4 (C-6B, C-6D), 55.6 (Me (OMP)), 
52.1, 50.0 (C-2B, C-2D), 37.8 (CH2(Lev)), 29.7 (CH3(Lev)), 28.2 
(CH2(Lev)), 27.6-27.2 (C(CH3)3), 23.3-20.4 (C(CH3)3); ESI MS: m/z: calcd 
for C98H114F6N2O28Si2Na: 1960.7; found: 1960.7 [M+Na]
+. 
4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-
D-galactopyranosyl)-(1→4)-O-(benzyl 2-O-benzoyl-3-O-benzyl-β-D-
glucopyranosyluronate)-(1→3)-O-(2-deoxy-2-trifluoroacetamido-β-D-
galactopyranosyl)-(1→4)-benzyl 2-O-benzoyl-3-O-benzyl-β-D-
glucopyranosiduronate (12): An excess of (HF)n·Py (110 µL, 4.2 mmol) 
was added at 0°C under an argon atmosphere to a solution of 11 (41 mg, 
0.021 mmol) in dry THF (2.0 mL). After 20 h at 0ºC the mixture was 
diluted with CH2Cl2 and washed with H2O and saturated NaHCO3 
solution until neutral pH. The organic layers were dried (MgSO4), filtered 
and concentrated in vacuo to give 12 (35 mg, quantitative) as a white 
amorphous solid. TLC (CH2Cl2-MeOH 20:1) Rf 0.43; 
1H-NMR (400 MHz, 
CDCl3/CD3OD 5:1): δ 7.92 (m, 4H, Ar), 7.55 (m, 2H, Ar), 7.43-7.00 (m, 
24H, Ar), 6.78 (m, 2H, Ar), 6.61 (m, 2H, Ar), 5.28 (m, 2H, H-2A or C, 
CH2(Bn)), 5.19 (d, 1H, CH2(Bn)), 5.12-5.07 (m, 2H, H-2A or C, CH2(Bn)), 
5.00-4.96 (m, 2H, CH2(Bn), H-1A or C), 4.92-4.85 (2d, 2H, CH2(Bn)), 
4.77 (d, 1H, J1,2 = 7.4 Hz, H-1A or C), 4.70 (dd, 1H, J2,3 = 11.2 Hz, J3,4  = 
3.0 Hz, H-3D), 4.51 (m, 4H, CH2(Bn), H-1B, H-1D), 4.32-4.17 (m, 3H, H-
2D, H-4A, H-4C), 4.03-3.93 (m, 4H, H-5A, H-5C, H-4D, H-2B), 3.83-3.66 
(m, 9H, H-3B, H-3A, H-3C, H-4B, 1 x H-6B, 1 x H-6D, Me (OMP)), 3.48 
(dd, 1H, H-6D), 3.33 (dd, 1H, H-6B), 3.30-3.24 (m, 2H, H-5B, H-5D), 
2.76-2.48 (m, 4H, CH2(Lev)), 2.14 (s, 3H, CH3(Lev)); 
13C-NMR (100 MHz, 
CDCl3/CD3OD 5:1, selected data from HSQC experiment): δ 104.7, 104.5 
(C-1A, C-1C), 103.7 (C-1B, C-1D), 83.8 (C-3A, C-3C), 82.8 (C-3B), 79.8 
(C-4A, C-4C, 2 x CH2(Bn)), 79.6 (C-5B, C-5D), 78.0, 77.8 (C-5A, C-5C), 
76.9 (C-3D), 76.2, 76.1 (C-2A, C-2C), 71.9, 71.4 (2 x CH2(Bn)), 71.9 (C-
4B), 69.7 (C-4D), 66.0, 65.5 (C-6B, C-6D), 59.4 (Me (OMP)), 55.9, 54.7 
(C-2B, C-2D); HR MS: m/z: calcd for C82H82F6N2O28Na: 1679.4850; 
found: 1679.4838 [M+Na]+. 
4-Methoxyphenyl O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-
galactopyranosyl)-(1→4)-O-( β-D-glucopyranosyluronic acid)-(1→3)-
O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1→4)-
β-D-glucopyranosiduronic acid (15) Compound 12 (14 mg, 8.4 µmol) 
and sulfur trioxide–trimethylamine complex (47 mg, 0.34 mmol) were 
dissolved in dry DMF (1.5 mL) and heated at 100ºC for 30 min using 
microwave radiation (20 W average power). The reaction vessel was 
cooled and Et3N (300 µL), MeOH (1 mL) and CH2Cl2 (1 mL) were added. 
The solution was layered on the top of a Sephadex LH 20 
chromatography column which was eluted with CH2Cl2-MeOH (1:1) to 
obtain 13 as triethylammonium salt (20 mg, quantitative). TLC 
(EtOAc/pyridine/H2O/AcOH 12:5:3:1) Rf 0.28; 
1H-NMR (400 MHz, 
CD3OD): δ 7.98 (m, 4H, Ar), 7.63 (m, 2H, Ar), 7.51-7.07 (m, 24H, Ar), 
6.84 (m, 2H, Ar), 6.72 (m, 2H, Ar), 5.45 (d, 1H, CH2(Bn)), 5.37-5.24 (m, 
5H, H-2A, H-2C, H-1A, CH2(Bn)), 5.11 (d, 1H, CH2(Bn)), 5.04-4.94 (m, 
4H, CH2(Bn), H-1C, H-3D), 4.87-4.81 (m, 3H, H-4D, H-4B, H-1D), 4.72 (d, 
1H, J1,2 = 8.1 Hz, H-1B), 4.61 (d, 1H, CH2(Bn)), 4.55-4.22 (m, 8H, 
CH2(Bn), 3 x H-6B/D, H-4A, H-4C, H-2D, H-5A), 4.18-4.08 (m, 3H, H-5C, 
H-2B, H-6B or D), 4.03-3.96 (m, 3H, H-3B, H-3A, H-5B or D), 3.89 (t, 1H, 
J2,3 = J3,4 = 8.6 Hz, H-3C), 3.81 (m, 1H, H-5B or D), 3.72 (s, 3H, Me 
(OMP)), 3.17 (q, 24H, Et3NH
+), 2.84-2.59 (m, 4H, CH2(Lev)), 2.16 (s, 3H, 
CH3(Lev)), 1.28 (t, 36H, Et3NH
+); 13C-NMR (100 MHz, CD3OD, selected 
data from HSQC experiment): δ 100.9 (C-1C), 99.6 (C-1A), 99.4 (C-1B), 
99.3 (C-1D), 79.7 (C-3C), 79.2 (C-3A), 76.3 (C-4A, C-4C), 75.2 (C-4B), 
74.9 (C-3B or C-5B or D), 74.4 (CH2(Bn)), 74.3 (C-5C), 74.2 (C-5A), 73.7 
(CH2(Bn)), 73.2 (C-5B or D), 72.9 (C-3B or C-5B or D), 72.5 (C-2A, C-2C), 
71.1 (C-4D), 70.3 (C-3D), 67.5, 67.0 (C-6B, C-6D), 67.4, 66.7 (CH2(Bn)), 
54.5 (Me (OMP)), 52.1 (C-2B), 50.5 (C-2D); ESI MS: m/z: calcd for 
C82H79F6N2O40NaKS4: 2035.3; found: 2035.3 [M+Na+K+H]
-. 
H2O2 (30%, 0.33 mL) and an aqueous solution of LiOH (0.7 m, 0.20 mL) 
were added at 0ºC to a solution of 13 (20 mg, 8.4 µmol) in THF (0.9 mL). 
After stirring for 20 h at room temperature, MeOH (1.75 mL), H2O (0.5 
mL) and an aqueous solution of NaOH (4 m, 0.42 mL) were added. After 
stirring for 48 h at room temperature, the reaction mixture was 
neutralized with Amberlite IR-120 (H+) resin, filtered, and concentrated to 
give the desired diamine intermediate. Triethylamine (32 µL, 0.23 mmol) 
and acetic anhydride (32 µL, 0.34 mmol) were added to a cooled (0ºC) 
solution of this diamine derivative in dry MeOH (2.0 mL). After stirring for 
2 h at r.t., Et3N (300 µL) was added and the mixture was concentrated to 
dryness. The residue was purified by silica gel column chromatography 
(EtOAc-MeOH-H2O 16:5:3 + 1% Et3N) to give 14. This compound was 
then dissolved in H2O (2 mL) and Amberlite IR-120 H
+ resin was added 
(pH = 3.0). The mixture was immediately filtered, treated with 0.04 M 
NaOH (pH = 7.1) and lyophilized. The white solid was finally eluted from 
a column of Dowex 50WX4-Na+ (H2O-MeOH 9:1) to obtain 14 as sodium 
salt (8 mg, 62%) after lyophilization. TLC (EtOAc/pyridine/H2O/AcOH 
6:5:3:1) Rf 0.27; 1H-NMR (400 MHz, D2O): δ 7.54-7.29 (m, 10H, Ar), 7.04 
(m, 2H, Ar), 6.91 (m, 2H, Ar), 4.95-4.93 (m, 2H, CH2(Bn), H-1A), 4.87 (d, 
1H, CH2(Bn)), 4.77-4.67 (m, 4H, H-4B, H-4D, CH2(Bn)), 4.59 (d, 1H, J1,2 
= 8.2 Hz, H-1B), 4.54 (d, 1H, J1,2 = 8.3 Hz, H-1D), 4.44 (d, 1H, J1,2 = 7.6 
Hz, H-1C), 4.19 (dd, 1H, J5,6a = 3.6 Hz, J6a,6b = 10.8 Hz, H-6B or D), 4.15-
3.88 (m, 10H, 3 x H-6B/D, H-4A, H-2B, H-4C, H-2D, H-3B, H-5B, H-5D), 
3.82-3.76 (m, 2H, H-5A, H-3D), 3.75 (s, 3H, Me (OMP)), 3.67 (m, 2H, H-
2A, H-3A), 3.62 (d, 1H, J4,5 = 9.7 Hz, H-5C), 3.55 (t, 1H, J2,3 = J3,4 = 9.2 
Hz, H-3C), 3.48 (t, 1H, H-2C), 2.01-2.00 (2s, 6H, NHAc); 13C-NMR (100 
MHz, D2O, selected data from HSQC experiment): δ 128.9-114.8 (Ar), 
103.6 (C-1C), 101.1 (C-1A), 99.9 (C-1D), 99.6 (C-1B), 80.9 (C-3A, C-3C), 
76.7 (C-5A), 76.6 (C-4A), 76.5-75.7 (C-4C, C-4B, C-3B, C-5C), 75.4 (C-
4D), 73.8, 73.6 (CH2(Bn)), 71.9 (C-5B, C-5D), 71.7 (C-2A), 71.3 (C-2C), 
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70.3 (C-3D), 67.5, 66.6 (C-6B, C-6D), 55.6 (Me (OMP)), 52.5 (C-2D), 
51.3 (C-2B), 22.4 (NHAc); ESI MS: m/z: calcd for C49H57N2O36Na3KS4: 
1485.1; found: 1484.8 [M+3Na+K+H]-. 
A solution of 14 (4.2 mg, 2.8 µmol, sodium salt) in H2O/MeOH (3.6 
mL/0.4 mL) was hydrogenated in the presence of 20% Pd(OH)2/C (9 mg). 
After 24 h, the suspension was filtered over celite, concentrated, and 
lyophilized to give 15 as a white amorphous solid (3.4 mg, sodium salt, 
92%). 1H-NMR (400 MHz, D2O): δ 7.03 (m, 2H, Ar), 6.91 (m, 2H, Ar), 
4.95 (d, 1H, J1,2 = 7.9 Hz, H-1A), 4.73 (d, 1H, J3,4 = 1.9 Hz, H-4B), 4.66 (d, 
1H, J3,4 = 2.5 Hz, H-4D), 4.56 (d, 1H, J1,2 = 7.9 Hz, H-1B), 4.52 (d, 1H, 
J1,2 = 7.6 Hz, H-1D), 4.41 (d, 1H, J1,2 = 7.9 Hz, H-1C), 4.26-4.14 (m, 4H, 
H-6B, H-6D), 4.08-3.99 (m, 4H, H-5B, H-5D, H-2B, H-3B), 3.87-3.76 (m, 
4H, H-2D, H-3D, H-4A, H-5A), 3.74 (s, 3H, Me (OMP)), 3.72-3.64 (m, 2H, 
H-4C, H-3A), 3.61-3.50 (m, 3H, H-5C, H-2A, H-3C), 3.32 (t, 1H, H-2C), 
1.98-1.96 (2s, 6H, NHAc); 13C-NMR (100 MHz, D2O, selected data from 
HSQC experiment): δ 117.9-114.6 (Ar), 103.6 (C-1C), 101.3 (C-1B, C-
1D), 100.8 (C-1A), 81.6 (C-4A, C-4C), 76.3 (C-5C), 76.1 (C-5A), 75.7 (C-
4B), 75.3 (C-4D), 75.0 (C-3B), 73.7 (C-3A), 73.4 (C-3C), 72.2 (C-5B, C-
5D), 72.0 (C-2A), 71.9 (C-2C), 69.9 (C-3D), 67.5 (C-6B, C-6D), 55.6 (Me 
(OMP)), 52.2 (C-2D), 51.3 (C-2B), 22.2 (NHAc); ESI MS: m/z: calcd for 
C35H44N2O36Na4S4: 644.0; found: 643.8 [M+4Na]
2-.  
Fluorescence polarization assays 
Fluorescence polarization measurements were performed in 384-well 
microplates (black polystyrene, non-treated, Corning). The fluorescence 
polarization was recorded using a TRIAD multimode microplate reader 
(from Dynex), with excitation and emission wavelengths of 485 and 535 
nm, respectively. The fluorescent probe (a fluorescein labelled heparin-
like hexasaccharide previously prepared in our lab[12]) was dissolved in 
PBS buffer (10 mM, pH 7.4). Recombinant human midkine (Peprotech) 
was dissolved in PBS buffer (10 mM, pH 7.4) containing 1% BSA. 
Synthetic oligosaccharides 14-27 were dissolved in PBS buffer (10 mM, 
pH 7.4). 
For direct binding assay between the fluorescent probe and midkine, 15 
µL of a 20 nM probe solution and 15 µL of a series of midkine solutions, 
ranging from 1.5 µM to 24 nM, were transferred to the microplate wells. 
The final sample volume in each well was 30 µL. All samples were 
performed in replicates of three. The microplate was shaked in the dark 
for 5 min, before reading. Blank wells contained 15 µL of midkine solution 
(1.5 µM) and 15 µL of PBS buffer and their measurements were 
substracted from all values. Wells containing 15 µL of the fluorescent 
probe solution (20 nM) and 15 µL of PBS buffer plus 1% BSA gave the 
background polarization of the probe solution, in the absence of protein. 
The change in the fluorescence polarization (ΔP) was calculated by 
subtracting the background polarization of probe from the polarization 
value of the sample solutions. The ΔP values were plotted against 
midkine concentrations and the obtained binding curve was fitted to the 
equation for a one-site binding model y = ΔP maxx/KD+x where ΔPmax is 
the maximum value approached with increasing concentrations of 
midkine and KD is the dissociation constant of the probe-midkine 
interaction. 
For the initial screening assays at a fixed concentration of inhibitor, 10 µL 
of a 40 nM probe solution and 20 µL of a 94 nM midkine solution were 
mixed with 10 µL of a 100 µM inhibitor solution. The total sample volume 
in each well was 40 µL and the final buffer composition was PBS + 0.5% 
BSA. The final concentrations of inhibitor, fluorescent probe and midkine 
in each well were 25 µM, 10 nM and 47 nM, respectively.  After stirring 
for 5 min in the dark, fluorescence polarization was recorded. Two control 
samples were included in the study. The first one only contained 
fluorescent probe and afforded the expected value for 100% inhibition; 
the second one contained midkine and probe, in the absence of inhibitor, 
and gave the polarization value corresponding to 0% inhibition. Blank 
wells contained 20 µL of midkine solution (94nM) and 20 µL of PBS 
buffer and their measurements were subtracted from all values. All 
samples were performed in replicates of three. 
For the determination of the IC50 values, we recorded the fluorescence 
polarization from wells containing 20 µL of a 94 nM midkine solution and 
10 µL of a 40 nM probe solution in the presence of 10 µL of inhibitor 
solution, with concentrations ranging from 100 µM to 100 nM. The total 
sample volume in each well was 40 µL and the final buffer composition 
was PBS + 0.5% BSA. The final concentrations of fluorescent probe and 
midkine in each well were 10 nM and 47 nM, respectively, while the final 
inhibitor concentration ranged from 25 µM to 25 nM. The average 
polarization values of three replicates were plotted against the logarithm 
of inhibitor concentration. The curve was fitted to the equation for a one-
site competition: y = A2 + (A1-A2)/[1+10^(x-logIC50)] where A1 and A2 are, 
respectively, the maximal and minimal values of polarization, and IC50 is 
the concentration that results in 50% inhibition.  
NMR Spectroscopy: NMR experiments were recorded in Bruker 
spectrometers of 500 and 600 MHz (Bruker Avance 500, and Bruker 600 
Avance III) Fitted with inverse triple resonance probes. Samples for 
structural analysis were prepared in D2O 100% at concentrations ca. 
1mM, and using low temperature (between 280 and 283K in order to 
increase the population of the most stable conformation, variations were 
imposed by the overlapping with the residual water signal). Experiments 
were recorded using the gradient selected or enhanced pulse programs 
from the manufacturer pulse sequences library. COSY-DQF, TOSCY, 
and NOESY were recorded using States – TTPI detection schemes in F1 
and echo-antiecho with sensitivity improvement for HSQC experiments. 
1D selective experiments have been acquired using 1D-DPFGSE 
sequences for selection.[27] 
Experimental distances have been calculated using the ISPA 
approximation, obtaining the initial growing rates of the dipolar rate 
constant by fitting the growing curve of the NOE versus the mixing time 
to a mono exponential equation.[21, 28] 
STD-NMR experiments have been performed and STD amplification 
factors (STD-AF0) were calculated from the STD initial slopes. To do so, 
the evolution of the STD-AF with the saturation time (tsat) was fitted to the 
equation STD-AF(t) = a(1-exp(-bt)), where the parameter a represents 
the asymptotic maximum of the STD build-up curve (STDmax), b is a rate 
constant related to the relaxation properties of a given proton that 
measures the speed of the STD build-up (ksat), and t is the saturation 
time (tsat). Thus, the STD-AF0 values were obtained as the product of the 
ab coefficients.[26b] 
Molecular Dynamics: In all cases, the starting geometries were 
generated from the available data[29] deposited in the Protein Data Bank 
(pdb code 1hpn) and modified accordingly. The topologies were built 
employing the residues and the set of partial charges published by Perez 
et al[30] (the latter developed under the framework of the set of 
parameters for carbohydrates PIM[31]) and the force fields parm91[32] of 
Amber 12 and glycam_06[33] together with the set of Altona parameters 
for sulfates[34]. In the case of IdoA containing tetrasaccharides, two 
independent starting geometries were built, one with the IdoA residue in 
the chair 1C4 conformation and one with the IdoA in the 
2SO
 skew boat 
geometry. Each of these models was immersed in a 10Å-sided cube of 
pre-equilibrated TIP3P water molecules. 
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To equilibrate the system we have followed a protocol consisting of 10 
steps. Firstly, only the water molecules and ions were minimized. Then 
the system is heated to 300 K by a 3 ps MD simulation, allowing only 
water molecules and ions to move. Next, the whole system is minimized 
by four consecutive steps imposing positional restraints on the solute, 
with a force constant decreasing step by step from 20 to 5 kcal/mol. 
Finally, a non-restraint minimization (100 steps) is carried out.  
The production dynamics simulations were accomplished at a constant 
temperature of 300 K (by applying the Berendsen coupling algorithm[35] 
for the temperature scaling) and constant pressure (1 bar). The Particle 
Mesh Ewald Method[36] (to introduce long-range electrostatic effects) and 
periodic boundary conditions were also turned on. The SHAKE algorithm 
for hydrogen atoms, which allows using a 2 fs time step, was also 
employed. Finally, a 9 Å cutoff was applied for the Lennard-Jones 
interactions.  
MD simulations have been performed with the Pmemd module of Amber 
12, with explicit treatment of the 10 12 hydrogen bond potential, in 
agreement with the parameters set for sulfates. The trajectory 
coordinates were saved each 0.5 ps. The overall length for the 
simulations was 200 – 500 ns. The data processing of the trajectories 
were done with the ptraj module of Amber 12, except for the Cremer-
Pople puckering coordinates, which were calculated with the Carnal 
module of Amber 5.0.  
The time-averaged restrained molecular dynamics were run following the 
above-commented protocol. In the production step, a single NOE-derived 
distance, between H2 and H5 protons of the IdoA residue (Table 2), was 
imposed as time-averaged constraint, applying an r−6  averaging. The 
equilibrium distance range was set to rexp −  0.1 Å ≤ rexp ≤ rexp  + 0.1 Å. 
Trajectories were run at 278 K, with a decay constant of 800 ps and a 
time step of 1 fs. The force constants rk2  and rk3 used in each case go 
from 25 to 45 kcal mol−1 A−2. The overall length for the simulations was 8 
ns for the tar-MD simulations. The coordinates were saved each 
picosecond, thus, obtaining tar MD trajectories of 8000 frames each. 
Convergence within the equilibrium distance range was obtained in all 
cases. The analysis of the tar -MD trajectories has been carried out with 
the ptraj module of AMBER 11.[33a] This protocol has been previously 
discussed in detail by us.[23]  
Docking: Docking has been performed using Induced Fit Docking (IDF) 
as implemented in Glide module of Maestro suite.[37] The complexes 
structures were constructed using the module AutodockTools 1.5.6 from 
Autodock Vina.  The model 3 from the NMR ensemble for midkine-A 
deposited in the Protein Data Bank (pdb code: 2LUT) was used as model 
of the protein[25b] and minimised structures taken from the MD-tar of the 
tetrasaccharides were used for the carbohydrate structures. The initial 
models were calculated using a centred box including the complete 
protein with a grid of 1 Å. The docking was performed considering the 
complete set of interactions of all the residues within 12 Å or the residues 
described previously as potential interacting with the ligand for midkine-B. 
The clusters, numbered according the 2LUT sequence, were: Cluster 1: 
K82-R84-K105; Cluster2: Q89-K90-L92; Cluster3: R38-R47; Cluster4: 
K48-K50-R52; Hinge: K58-K59. Both approximations give similar results.  
A 30 Å sided cubic grid from the centroid of the ligand was generated. 
The ten lowest energy conformers of each ligand were submitted to 
flexible SP docking using Glide. The sampling of ring conformations was 
turned off. The penalization of the non-planar conformations for amide 
type torsions and the sampling of nitrogen inversions were turned on. A 
distance dependent dielectric constant of 4 was used and post-docking 
minimization was performed. 
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Analysis of oligosaccharide-protein 
interactions: we have studied the 3D 
solution structure of synthetic 
chondroitin sulfate tetrasaccharides 
and their interaction with midkine by 
using a combination of different 
techniques: fluorescence polarization, 
NMR spectroscopy, molecular 
dynamics and docking. Our results 
provide new information on the 
relationship between the chondroitin 
sulfate structure and its binding to 
midkine. 
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